This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Heterosubtypic Immune Responses to Influenza in Older People

This study has been completed.
Sponsor:
Collaborators:
Centers for Disease Control and Prevention
Public Health England
Novartis
Information provided by (Responsible Party):
University Hospitals, Leicester
ClinicalTrials.gov Identifier:
NCT00798343
First received: November 25, 2008
Last updated: June 2, 2014
Last verified: June 2014
  Purpose

Vaccination is the principal means of combating epidemic and pandemic influenza. As vaccines induce relatively strain-specific and short-lived antibody responses, annual immunisation with regularly updated vaccine is recommended for seasonal influenza, but would not be expected to protect against a pandemic event. In clinical trials among young adults, at least two doses of avian influenza H5 or H9 subunit vaccine are needed to induce moderate antibody responses. However, studies including older subjects have unexpectedly found that some people aged over 65 yrs have pre-vaccination neutralising antibody to influenza H5 and H9 respectively. These subjects mount a robust antibody response to single dose H5 or H9 pandemic vaccine, suggesting that they are effectively primed to at least some strains of avian influenza.

This exploratory proposal focuses on those elderly subjects whose immune systems already exhibit antibodies to H5 with a goal of investigating the humoral and cellular basis of the immune response to seasonal and pandemic vaccination. We will examine neutralising antibody responses to a range of human and non-human influenza viruses before and after seasonal and pandemic vaccination and evaluate cellular B and T cell immune responses before and after pandemic H5 vaccination


Condition Intervention Phase
Influenza Biological: Seasonal vaccine Biological: H5 vaccine Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Evaluation of Heterosubtypic Immune Responses in Older People Before and After Seasonal and Pandemic Influenza Vaccination

Resource links provided by NLM:


Further study details as provided by University Hospitals, Leicester:

Primary Outcome Measures:
  • Neutralising antibody to influenza subtypes [ Time Frame: 18 months ]

Secondary Outcome Measures:
  • Reactogenicity (local and systemic) to H5N1 vaccine [ Time Frame: 18 months ]

Enrollment: 292
Study Start Date: January 2009
Study Completion Date: September 2013
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Seasonal vaccine
Seasonal influenza vaccination
Biological: Seasonal vaccine
Non-adjuvanted seasonal influenza vaccine (total dose 45ug)
Other Name: Aggripal
Experimental: Pandemic vaccine
MF59-adjuvanted H5N1 monovalent vaccine
Biological: H5 vaccine
MF59-adjuvanted A/Vietnam/1194 H5N1 vaccine 7.5ug dose
Other Name: Aflunov

Detailed Description:

STUDY OBJECTIVES:

Immunological objectives

  • To evaluate heterosubtypic neutralising antibody to influenza viruses in older people
  • To evaluate heterosubtypic neutralising antibody responses to human and non-human influenza viruses following seasonal influenza vaccine
  • To evaluate homologous and heterosubtypic neutralising antibody responses to human and non-human influenza viruses after MF59-adjuvanted H5N1 vaccine;
  • To evaluate cellular B and T cell responses to influenza H5 in non-exposed subjects who exhibit anti-H5 neutralising antibodies before and after seasonal (TIV) or pandemic H5 vaccination
  • To identify epitopes on the influenza haemagglutinin to which anti-H5 neutralising antibodies in sera from non-exposed subjects are directed Safety Objectives
  • To evaluate safety of one or two IM doses of MF59-adjuvanted A/Vietnam/1194/2004 (H5N1) influenza vaccine, containing 7.5 μg of H5 antigen in adult subjects
  • To evaluate safety of one IM dose of seasonal influenza vaccine, containing 15 μg of H1, H3 and B antigen in adult subjects

Hypotheses:

  • Heterosubtypic cross reacting antibodies to influenza exist in some elderly subjects and can be boosted by a single dose of (a) seasonal TIV or (b) pandemic influenza vaccination
  • Heterosubtypic cross reacting antibodies to influenza do not exist in younger subjects and cannot be induced by (a) seasonal TIV or (b) pandemic influenza vaccination
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Subjects aged over 18 years of age, mentally competent, who have signed an informed consent form after having received a detailed explanation of the study protocol;
  2. Subjects willing to be enrolled in the vaccine study if appropriate from prescreening blood test results
  3. In good health as determined by:

    1. medical history,
    2. physical examination,
    3. clinical judgment of the Investigator;
  4. Able to understand and comply with all study procedures and to complete study diaries, can be contacted, and will be available for study visits

Exclusion Criteria:

  1. Receipt of another investigational agent within 4 weeks, or before completion of the safety follow-up period in another study, whichever is longer, prior to enrollment and unwilling to refuse participation in another clinical study through the end of the study;
  2. Subjects who experienced any acute disease or infection requiring systemic antibiotic or antiviral therapy (chronic antibiotic therapy for urinary tract prophylaxis is acceptable) within the past 7 days before Visit 1 or any visit where trial vaccination is planned;
  3. Subjects who experienced fever (within 3 days prior to Visit 1;
  4. Subjects who are pregnant or breastfeeding;
  5. Females of childbearing potential who refuse to use an acceptable method of birth control for the duration of the study.
  6. Subjects with any serious disease, such as:

    1. cancer,
    2. autoimmune disease (including rheumatoid arthritis),
    3. progressive chronic pulmonary disease (stable controlled respiratory disease including asthma is allowed),
    4. acute or progressive hepatic disease,
    5. acute or progressive renal disease;
  7. Subjects for whom elective surgery is planned during the study period;
  8. Subjects with bleeding diathesis;
  9. Subjects with hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein, neomycin or polymyxin or any other component of the study vaccine;
  10. Subjects with a history of any neurological symptoms or signs, or anaphylactic shock following administration of any vaccine;
  11. Subjects with known or suspected impairment/alteration of immune function, for example, resulting from:

    1. receipt of immunosuppressive therapy (any corticosteroid therapy or cancer chemotherapy),
    2. receipt of immunostimulants,
    3. receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within 3 months prior to Visit 1 or planned during the full length of the study,
    4. high risk for developing an immunocompromising disease;
  12. Receipt of another vaccine within 3 weeks prior to Visit 1 or planned vaccination within 3 weeks following the last study vaccination;
  13. Subjects with a history of (or current) drug or alcohol abuse that in the investigator's opinion would interfere with safety of the subject or the evaluation of study objectives;
  14. Subjects with any condition, which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00798343

Locations
United Kingdom
University Hospitals Leicester
Leicester, Leicestershire, United Kingdom, LE1 5WW
Sponsors and Collaborators
University Hospitals, Leicester
Centers for Disease Control and Prevention
Public Health England
Novartis
Investigators
Principal Investigator: Iain Stephenson, FRCP University of Leicester
  More Information

Responsible Party: University Hospitals, Leicester
ClinicalTrials.gov Identifier: NCT00798343     History of Changes
Other Study ID Numbers: UHL10548
MRC 82292
Study First Received: November 25, 2008
Last Updated: June 2, 2014

Keywords provided by University Hospitals, Leicester:
Influenza, heterosubtypic immune responses

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 25, 2017